Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder
Portfolio Pulse from Vandana Singh
Monopar Therapeutics' stock surged after securing a licensing agreement with AstraZeneca's Alexion for ALXN-1840, a treatment for Wilson's disease. Monopar will handle future development and commercialization, with payments to Alexion based on sales milestones.
October 24, 2024 | 5:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Monopar Therapeutics' stock surged over 400% following a licensing agreement with AstraZeneca for ALXN-1840, a treatment for Wilson's disease. Monopar will lead future development and commercialization efforts.
The licensing agreement with AstraZeneca for a previously terminated Phase 3 candidate has significantly boosted investor confidence in Monopar, leading to a 400% increase in stock price. The potential for future development and commercialization of ALXN-1840 presents a promising opportunity for Monopar.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
AstraZeneca's Alexion has licensed ALXN-1840 to Monopar Therapeutics, transferring future development and commercialization responsibilities. AstraZeneca will receive upfront payments and royalties based on sales milestones.
AstraZeneca's decision to license ALXN-1840 to Monopar indicates a strategic shift, allowing them to focus on other priorities while still benefiting from potential future sales through royalties. The impact on AstraZeneca's stock is neutral as the drug was previously terminated.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70